Supplementary Figures include the survival curves of the significant MR genes which did not present the same profile curve on GSE21501, GSE28735 and MEXP2780 arrays. The selection of MRs followed these criteria: (a) they should be verified in all three arrays and also (b) they should present the same profile curve (e.g., if low gene expression was associated with greater chances of survival in one array, the same feature should be observed in the next arrays); if not, the data were considered conflicting and were then discarded. Survival curves were estimated by Kaplan-Meier method. LogRank test was used to compare the survival and Hazard Ratios with 95% confidence intervals were calculated.

Supplementary Figure S1. Kaplan-Meier curve of ZNF407. GSE21501 was the only array which presented significant difference between low-high ZNF407 expression (p-value=0.01634). HR have indicated 1.85 greater chances of survival for patients who had low ZNF407 expression.
**Supplementary Figure S2.** Kaplan-Meier curve of *MYSM1*. Low-high *MYSM1* expression comparison was significant different on the GSE21501 array, with *p*-value=0.01866. Patients with high *MYSM1* expression had 0.34 greater chances of survival.
Supplementary Figure S3. Kaplan-Meier curve of ZZZ3. GSE21501 and GSE28935 were the only arrays which presented significant difference between low-high ZZZ3 expression (p-value=0.00253 and p-value=0.02784, respectively). HR have indicated 0.32 greater chances of survival for patients who had high ZZZ3 expression in GSE21501, whereas patients with low ZZZ3 expression had 2.95 greater chances of survival in GSE28735. Both survival curves were significant, however, the data were discordant.
**Supplementary Figure S4.** Kaplan-Meier curve of *ZFP91*. Low-high *ZFP91* expression comparison was significant different on the GSE21501 and GSE28735 arrays, with *p*-value=0.01655 and *p*-value=0.0462, respectively. Patients with low *ZFP91* expression had 1.83 greater chances of survival in GSE21501, whereas HR have indicated 0.31 greater chances of survival for patients who had high *ZFP91* expression in GSE28735. Both survival curves were significant, however, the data were discordant.
Supplementary Figure S5. Kaplan-Meier curve of ZNF41. Low-high ZNF41 expression comparison was significant different on the GSE21501 array, with $p$-value=0.01857. Patients with low ZNF41 expression had 1.9 greater chances of survival.
Supplementary Figure S6. Kaplan-Meier curve of HSF4. GSE21501 and GSE28735 were the only arrays which presented significant difference between low-high HSF4 expression ($p$-value=0.00654 and $p$-value=0.04136, respectively). Patients with low HSF4 expression had 2.08 greater chances of survival in GSE21501, whereas HR have indicated 0.31 greater chances of survival for patients who had high HSF4 expression in GSE28735. Both survival curves were significant, however, the data were discordant.
Supplementary Figure S7. Kaplan-Meier curve of ARID4B. GSE21501 and GSE28935 were the only arrays which presented significant difference between low-high ARID4B expression \( (p\text{-value}=0.00571 \text{ and } p\text{-value}=0.0251, \text{ respectively}) \). HR have indicated 0.33 greater chances of survival for patients who had high ARID4B expression in GSE21501, whereas patients with low ARID4B expression had 2.71 greater chances of survival in GSE28735. Both survival curves were significant, however, the data were discordant.
Supplementary Figure S8. Kaplan-Meier curve of *PRDM10*. GSE21501 and MEXP2780 were the only arrays which presented significant difference between low-high *PRDM10* expression (*p*-value=0.00032 and *p*-value=0.01617, respectively). Patients with high *PRDM10* expression had 0.275 and 0.25 greater chances of survival in GSE21501 and MEXP2780, respectively. Although the curves were significant on two arrays, the third array did not present significance, thus we could not include *PRDM10* as a possible pancreatic cancer biomarker in this work. However, more studies are necessary to demonstrate the role of *PRDM10* on pancreatic cancer.
Supplementary Figure S9. Kaplan-Meier curve of SMARCE1. Low-high SMARCE1 expression comparison was significant different on the GSE21501, GSE28935 and MEXP2780 arrays, with \( p \)-value=0.00153, \( p \)-value=0.00757 and \( p \)-value=0.00669, respectively. HR have indicated 0.275 greater chances of survival for patients who had high SMARCE1 expression in GSE21501, whereas in GSE28735 and MEXP2780 arrays, patients with low SMARCE1 expression had 3.15 and 3.13 greater chances of survival, respectively. In this case, we could not assume any data, despite all curves were significant, since data were conflicting.
Supplementary Figure S10. Kaplan-Meier curve of ZNF3. Low-high ZNF3 expression comparison was significant different on the GSE21501 and MEXP2780 arrays, with \( p\)-value=0.03884 and \( p\)-value=0.00158, respectively. Patients with low ZNF3 expression had 0.42 greater chances of survival in GSE21501, whereas HR have indicated 0.21 greater chances of survival for patients who had high ZNF3 expression in MEXP2870. Both survival curves were significant, however, the data were discordant.
ZNF280D

GSE21501

GSE28735

MEXP2780
Supplementary Figure S11. Kaplan-Meier curve of ZNF280D. Low-high ZNF280D expression comparison was significant different on the GSE21501, GSE28935 and MEXP2780 arrays, with \( p \)-value=0.0033, \( p \)-value=0.01128 and \( p \)-value=0.00121, respectively. HR have indicated 0.32 greater chances of survival for patients who had high ZNF280D expression in GSE21501, whereas in GSE28735 and MEXP2780 arrays, patients with low ZNF280D expression had 2.76 and 3.88 greater chances of survival, respectively. In this case, we could not assume any data, since data were conflicting.
Supplementary Figure S12. Kaplan-Meier curve of NFE2L2. GSE21501 was the only array which presented significant difference between low-high NFE2L2 expression ($p$-value=0.00551). HR have indicated 0.33 greater chances of survival for patients who had high NFE2L2 expression.